G9143 – Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)
HCPCS Level II code · G codes: Procedures / Professional Services (Temporary)
HCPCS codeG9143
- Long description
- Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)
- Short description
- Warfarin respon genetic test
- Pricing indicator
13Priced by the Medicare contractor (carrier)- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
M5DSpecialist - other- Added
- August 3, 2009
- Last change
- January 1, 2014 – No change
Frequently asked questions
What is HCPCS code G9143?
G9143 is a HCPCS Level II code for warfarin responsiveness testing by genetic technique using any method, any number of specimen(s).
Does Medicare cover G9143?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby G codes
- G9133 – Oncology; disease status; prostate cancer, limited to adenocarcinoma; hormone-responsive; clinical metastases or m1 at diagnosis (for use in a medicare-approved demonstration project)
- G9134 – Oncology; disease status; non-hodgkin's lymphoma, any cellular classification; stage i, ii at diagnosis, not relapsed, not refractory (for use in a medicare-approved demonstration project)
- G9135 – Oncology; disease status; non-hodgkin's lymphoma, any cellular classification; stage iii, iv, not relapsed, not refractory (for use in a medicare-approved demonstration project)
- G9136 – Oncology; disease status; non-hodgkin's lymphoma, transformed from original cellular diagnosis to a second cellular classification (for use in a medicare-approved demonstration project)
- G9137 – Oncology; disease status; non-hodgkin's lymphoma, any cellular classification; relapsed/refractory (for use in a medicare-approved demonstration project)
- G9138 – Oncology; disease status; non-hodgkin's lymphoma, any cellular classification; diagnostic evaluation, stage not determined, evaluation of possible relapse or non-response to therapy, or not listed (for use in a medicare-approved demonstration project)
- G9139 – Oncology; disease status; chronic myelogenous leukemia, limited to philadelphia chromosome positive and/or bcr-abl positive; extent of disease unknown, staging in progress, not listed (for use in a medicare-approved demonstration project)
- G9140 – Frontier extended stay clinic demonstration; for a patient stay in a clinic approved for the cms demonstration project; the following measures should be present: the stay must be equal to or greater than 4 hours; weather or other conditions must prevent transfer or the case falls into a category of monitoring and observation cases that are permitted by the rules of the demonstration; there is a maximum frontier extended stay clinic (fesc) visit of 48 hours, except in the case when weather or other conditions prevent transfer; payment is made on each period up to 4 hours, after the first 4 hours
- G9147 – Outpatient intravenous insulin treatment (oivit) either pulsatile or continuous, by any means, guided by the results of measurements for: respiratory quotient; and/or, urine urea nitrogen (uun); and/or, arterial, venous or capillary glucose; and/or potassium concentration
- G9148 – National committee for quality assurance - level 1 medical home
- G9149 – National committee for quality assurance - level 2 medical home
- G9150 – National committee for quality assurance - level 3 medical home
- G9151 – Mapcp demonstration - state provided services
- G9152 – Mapcp demonstration - community health teams
- G9153 – Mapcp demonstration - physician incentive pool
- G9156 – Evaluation for wheelchair requiring face to face visit with physician
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.